T-NBOMe

T-NBOMe
Clinical data
Other namesTNBOMe; NBOMe-T; NBOMe-tryptamine; Tryptamine-NBOMe; N-(2-Methoxybenzyl)tryptamine
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Possible psychedelic drug
ATC code
  • None
Identifiers
  • 2-(1H-indol-3-yl)-N-[(2-methoxyphenyl)methyl]ethanamine
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H20N2O
Molar mass280.371 g·mol−1
3D model (JSmol)
  • COC1=CC=CC=C1CNCCC2=CNC3=CC=CC=C32
  • InChI=1S/C18H20N2O/c1-21-18-9-5-2-6-15(18)12-19-11-10-14-13-20-17-8-4-3-7-16(14)17/h2-9,13,19-20H,10-12H2,1H3
  • Key:HJCSKFSDXDPIKM-UHFFFAOYSA-N

T-NBOMe, or TNBOMe, also known as NBOMe-T, NBOMe-tryptamine, or N-(2-methoxybenzyl)tryptamine, is a serotonin receptor modulator and possible psychedelic drug of the tryptamine family. It is the N-(2-methoxybenzyl) derivative of tryptamine.

The drug shows affinity for the serotonin 5-HT2 receptors, including for the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors (Ki = 89 nM, 47 nM, and 224 nM, respectively). It shows 46-fold higher affinity for the serotonin 5-HT2A receptor than tryptamine (Ki = 89 nM vs. 4,074 nM, respectively). T-NBOMe acts as a partial agonist of the serotonin 5-HT2A receptor (EC50Tooltip half-maximal effective concentration = 1,549 nM; EmaxTooltip maximal efficacy = 63%) and as a near-full agonist of the serotonin 5-HT2C receptor (EC50 = 35 nM; Emax = 94%), with 44-fold preference for activation of the serotonin 5-HT2C receptor over the serotonin 5-HT2A receptor. Whereas T-NBOMe had much higher affinity for the serotonin 5-HT2A receptor than tryptamine, it showed 89-fold lower activational potency at the serotonin 5-HT2A receptor than tryptamine and also had lower activational efficacy at the receptor. In an earlier study however, T-NBOMe showed much greater potency as an agonist of the serotonin 5-HT2A receptor (EC50 = 155 nM; Emax = 44%).

The chemical synthesis of T-NBOMe has been described.

T-NBOMe was first described in the scientific literature by Ralf Heim and colleagues in 1999. It emerged as a novel designer drug by early 2024. However, the properties and effects of T-NBOMe in humans are unknown and it is unclear whether T-NBOMe actually produces hallucinogenic effects.

See also